#USA #San Diego #Halozyme #GSK #ENHANZE

Halozyme and GSK Collaboration

Halozyme Therapeutics, Inc. has announced a significant collaboration with GSK, marking a pivotal expansion in the realm of oncology treatment. This agreement centers around the licensing of Halozyme's innovative ENHANZE® drug delivery technology, aimed at developing subcutaneous formulations for various oncology targets, including antibody-drug conjugates (ADCs). As part of this collaboration, GSK has gained the rights to use ENHANZE® for commercial purposes, furthering the potential for new treatment methods in cancer therapies.

A New Era in Cancer Treatment

One of the most important aspects of this partnership is its focus on subcutaneous delivery systems. Dr. Helen Torley, President and CEO of Halozyme, emphasized the potential benefits subcutaneous administration presents, stating that it could significantly improve the benefit-risk profile for patients undergoing treatment for cancer. The ability to deliver therapeutic agents via subcutaneous methods offers a more comfortable and convenient alternative to traditional intravenous administration, which often subjects patients to prolonged hospital visits and discomfort.

In her statement, Dr. Torley highlighted that this collaboration also signals Halozyme's first engagement in the subcutaneous delivery of ADCs, a promising evolution in treating various cancer types. The ENHANZE® technology has been recognized as a standard for rapid and efficient drug delivery, and with this new venture, Halozyme leverages its experience to assist in the development of groundbreaking oncology therapies.

Advancing Patient Care

Eric Richards, Senior Vice President at GSK, shared insights regarding the goals of this collaboration, stating that innovative approaches are essential to alleviate the treatment burden for cancer patients. The partnership seeks to explore how ENHANZE® can facilitate easier access and administration of cancer therapies, thus improving the overall treatment experience.

GSK is poised to provide an upfront payment to Halozyme, along with potential future milestone payments as clinical advancements are achieved. Halozyme is also set to receive royalties based on net sales of any products that incorporate their pioneering technology, presenting a mutually beneficial framework for both companies.

About ENHANZE® Technology

Halozyme has established itself as an industry leader with its ENHANZE® drug delivery solution. This technology utilizes a proprietary enzyme, rHuPH20, to enhance the subcutaneous administration of injected medications, thus minimizing the discomfort and logistical challenges often faced by patients. The platform has touched the lives of over a million patients worldwide through various commercialized products and is in collaboration with numerous biopharmaceutical companies including Roche, Pfizer, and AbbVie, among others.

Recently, Halozyme has expanded its technology portfolio to include Hypercon™ and Surf Bio's hyperconcentration technology, further enhancing its capabilities in drug delivery methods. Hypercon™ specifically aims to set new standards in drug and biologic hyperconcentration, thus allowing for reduced injection volumes while maintaining required dosages. This technology, combined with existing offerings, provides a robust framework for improving therapeutic delivery.

The Future of Oncology Innovations

As Halozyme continues to develop and innovate within the biopharmaceutical landscape, the collaboration with GSK is an exciting step towards enhancing patient care and ensuring that cutting-edge cancer therapies become more viable for widespread use. The first clinical trial connected to this collaboration is projected to begin in 2026, setting the stage for what promises to be a transformative advancement in the way cancer treatment is approached.

With Halozyme's commitment to improving patient outcomes through innovative therapies, combined with GSK's vast reach in medicine development, this collaboration exemplifies the shared vision of advancing oncology treatments. As the companies progress, the implications of their partnership could fundamentally change the landscape of cancer care, offering patients more convenient and effective treatment options while mitigating the challenges faced in traditional delivery methods.

For more insight into this exciting collaboration and the future of oncology therapeutic advancements, please visit Halozyme's website.